GTHX: G1 Therapeutics Inc. Amount of Cash per Share

G1 Therapeutics, Inc. (GTHX) relies on external contractors for drug manufacturing, minimizing risks through strict SLA contracts. The model scales via B2B deals with oncology centers, leveraging completed R&D and high patent margins. Growth is driven by the expanded application of COSELA and US government procurement. Cash per share demonstrates the business's liquidity, where the value 1.16 represents the current metric.
Analytical breakdowns for G1 Therapeutics, Inc.

This metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. This figure determines the issuer's financial autonomy and the risk of capital depletion at the current burn rate. For G1 Therapeutics, Inc. (GTHX), a sufficient cash reserve is critical to sustaining the expansion of the drug Cosela within oncology protocols. Analyzing cash per share allows for an assessment of the business's resilience to operating expenses. The trend line reflects the balance between the cash reserve and the value of the investor's stake.